Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Regenerated skin: discovery and clinical use == A process for inducing regeneration in skin was invented by Ioannis V. Yannas (then an assistant professor in the Fibers and Polymers Division, Department of Mechanical Engineering, at Massachusetts Institute of Technology) and John F. Burke (then chief of staff at Shriners Burns Institute in Boston, Massachusetts). Their initial objective was to discover a wound cover that would protect severe skin wounds from infection by accelerating wound closure. Several kinds of grafts made of synthetic and natural polymers were prepared and tested in a guinea pig animal model. By the late 1970s it was evident that the original objective was not reached. Instead, these experimental grafts typically did not affect the speed of wound closure. In one case, however, a particular type of collagen graft led to significant delay of wound closure. Careful study of histology samples revealed that grafts that delayed wound closure induced the synthesis of new dermis de novo at the injury site, instead of forming scar, which is the normal outcome of the spontaneous wound healing response. This was the first demonstration of regeneration of a tissue (dermis) that does not regenerate by itself in the adult mammal. After the initial discovery, further research led to the composition and fabrication of grafts that were evaluated in clinical trials.
The integument of Sinosauropteryx was closely compared to less controversial evidence of collagen fibers preserved in the ichthyosaur Stenopterygius. Although the collagen hypothesis claimed that the central shafts (rachises) of purported theropod feathers were actually misidentified examples of shaft-like collagen fibers, higher quality imagery showed that these similarities were artificial. The supposed shafts in ichthyosaur collagen were actually scratch marks, cracks, and crevasses created during preparation of one of the ichthyosaur specimens. On the other hand, the shafts in the Sinosauropteryx specimens were legitimate examples of fossilized structures. The collagen hypothesis also claims that Sinosauropteryx integument includes beaded structures similar to structures occasionally found in decaying collagen of modern sea mammals. However, this claim was also unsupported, with Smithwick et al. finding no evidence of the beaded structures which collagen hypothesis proponents identified on the specimens. The study proposes that some areas of the fossil preserved in three dimensions cast shadows which would have resembled beaded structures in low quality photographs. Other examples of purported collagen fibers in the tail area were revealed to be scratches, similar to those on the rest of the specimen. An area of the bone with an irregular surface was considered evidence that some collagen fibers were less decayed than others.
Derek Malcolm of the Evening Standard felt that the movie was a "dim reworking of Fatal Attraction" and noted: "Larter as the pathological minx is the best thing about it." Obsessed opened No. 1 in its opening weekend with $28 million, and making a total domestic gross of $68 million, becoming Larter's second highest-grossing film in North-America. Larter was nominated for a third time for a Teen Choice Award when she and Beyoncé were nominated for the Teen Choice Award for Choice Movie: Rumble at the 2009 Teen Choice Awards and an MTV Movie Award for Best Fight both for Obsessed. Larter reprised her role of Claire Redfield in Resident Evil: Afterlife (2010), which was filmed in 3D and saw her character ambushed and mentally manipulated by the fictional Umbrella Corporation, before she is rescued by Alice (Milla Jovovich). Like the previous Resident Evil entries, the film received negative reviews but became a major commercial success, earning $296 million worldwide. On returning to the role of Claire, Larter told JoBlo.com: "I guess people liked me as her... I'm excited that they brought me back... to work with the man [Paul W. S. Anderson] who really created this world and this vision was what excited me about joining this next installment". In 2010, Larter appeared as the title character in a short film for Absolut Vodka entitled "Lemon Drop". After the release of Afterlife, Larter went on hiatus to focus on her family.
=== Hypochondrogenesis === Hypochondrogenesis is caused by various COL2A1 mutations, including deletions, glycine substitutions, and truncations. These interfere with the formation of mature, triple-stranded type II collagen molecules, affecting collagen-rich tissues.
Sources: en.wikipedia.org
== Pharmacokinetics == Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy.
=== United States === Soy sauce production in the United States began in the Territory of Hawaii in 1905 by Yamajo Soy Co, which by 1909 was renamed the Hawaiian Soy Company Ltd. La Choy started selling hydrolyzed vegetable protein–based soy sauce in 1933. Until the popularization of authentic Chinese cuisine in the 1970s, some Americans pejoratively nicknamed the sauce "beetle juice". This slur's usage had heavily declined by 1976.
== Pyrogen removal (depyrogenation) == Pyrogens can often be difficult to remove from solution due to the high variability of their molecular weight. Pyrogens are also relatively thermally stable and insensitive to pH changes. However, several removal techniques exist.
Sources: en.wikipedia.org
Bidentate ligands bind to metal ions forming a chelate ring. Ligands of higher denticity form two or more chelate rings. Ethylenediamine, 2,2'-bipyridine, and 1,10-phenanthroline form C2N2M chelate rings. Just like in organic chemistry, 5- and 6-membered chelate rings predominate.
Most researchers define Avialae as branch-based clade, though definitions vary. Many authors have used a definition similar to "all theropods closer to birds than to Deinonychus", with Troodon being sometimes added as a second external specifier in case it is closer to birds than to Deinonychus. Avialae is also occasionally defined as an apomorphy-based clade (that is, one based on physical characteristics). Jacques Gauthier, who named Avialae in 1986, re-defined it in 2001 as all dinosaurs that possessed feathered wings used in flapping flight, and the birds that descended from them. Despite being currently one of the most widely used, the crown-group definition of Aves has been criticised by some researchers. Lee and Spencer (1997) argued that, contrary to what Gauthier defended, this definition would not increase the stability of the clade and the exact content of Aves will always be uncertain because any defined clade (either crown or not) will have few synapomorphies distinguishing it from its closest relatives. Their alternative definition is synonymous with Avifilopluma.
In immunocytochemistry experiments, one (polyclonal) antibody against CSP labeled the antennal sensillum, but the labeling was not restricted to sensory structures but rather diffused to the cuticle and supporting cells [3, 36]. A function of CSPs in lipid transport is consistent with a crucial role not only in insect general immunity, moth pheromone synthesis or locust behavioral phase change, but also in head development as described in honeybees [37]. CSPs have been proposed to mediate recognition of chemical signatures composed of cuticular lipids as for instance in ants [38]. However, it is not clear whether some CSPs are involved in chemical communications, others in development or other physiological roles. The functional CSP structure is bound with fatty acid molecules [5]. Other functional CSP structures have been shown to interact directly with exogenous compounds such as toxic chemical compounds (cinnamaldehyde) from plant oils [34]. So, CSPs expressed not only in arthropods, but also in bacteria, and apparently endowed with heterogeneous functions. CSPs can trigger innate immune pathways in plants [39].
The beans, which are sterile within their pods, and their surrounding pulp are removed from the pods and placed in piles or bins to ferment. Micro-organisms, present naturally in the environment, ferment the seeds. Yeasts produce ethanol, lactic acid bacteria produce lactic acid, and acetic acid bacteria produce acetic acid. The fermentation process, which takes up to seven days, produces several flavor precursors, that eventually provide the chocolate taste. After fermentation, the beans are dried to prevent mold growth. Where the weather permits it, this is done by spreading the beans out in the sun for five to seven days. The dried beans are then transported to a chocolate manufacturing facility. The beans are cleaned (removing twigs, stones, and other debris), roasted, and graded. Next, the shell of each bean is removed to extract the nib.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.